Sentences with phrase «pembrolizumab as»

We are excited to evaluate our technology in combination with pembrolizumab as a potential treatment for lung cancer, and about the promise it may hold for patients,» said Turnstone CEO Sammy Farah, PhD.

According to an international clinical trial led by Sylvia Adams, MD, associate professor of medicine, breast tumors shrank by more than 30 percent in 12 (23 percent) of 52 patients who received pembrolizumab as first - line therapy, and the disease stabilized in 9 additional patients (17 percent).

These results support the use of pembrolizumab as the new standard of care for advanced bladder cancer,» concluded Dr Necchi.

In Cohort B — those who received pembrolizumab as first - line therapy — 12 of 52 patients, or 23 percent, saw tumors shrink by more than 30 percent, while the disease was stabilized in nine of them, or 17 percent.

Patients in the chemotherapy arm who progressed were eligible to crossover to pembrolizumab as second line treatment — this occurred in 44 % of these patients.

Not exact matches

Researchers are currently testing pembrolizumab to determine if it has the same result in other cancers, as well as trying to combine pembrolizumab with other therapies.

The goals of Cohort B, for which survival data are not yet complete, were, primarily, to prove pembrolizumab's safety and, secondarily, to explore its efficacy as a first - line treatment.

KEYNOTE - 024 investigated the efficacy of pembrolizumab compared to standard of care with platinum - based chemotherapy in untreated patients with advanced NSCLC and high PD - L1 expression (defined as expression in at least 50 % of tumour cells).

In addition to helping patients live longer, more patients treated with pembrolizumab responded to treatment and for a longer duration than those treated with chemotherapy; the objective response rate — the percentage of patients whose tumours shrank or disappeared — was almost twice as high with pembrolizumab: 21 % compared to 11 % on chemotherapy.

We estimate that almost twice as many pembrolizumab responders will respond to the therapy for at least one year: 68 % versus 35 %.»

Once they identified this pathway, Hanks and colleagues conducted laboratory tests of a molecule that blocks melanoma cells from going stealth, enabling the immune system to mount a direct attack while also enhancing the function of current immunotherapies such as pembrolizumab and nivolumab.

PD -1-blocking agents such as nivolumab, pembrolizumab and atezolizumab are part of a class of drugs known as checkpoint inhibitors, and many cancer researchers are now trying to figure out how to enhance their activity by combining them with other types of drugs.

Checkpoint inhibitors such as ipilimumab, nivolumab and pembrolizumab have had a dramatic impact on treatment of several tumor types, including melanoma, lung cancer, head and neck cancers and others.

A Randomized, Phase III Trial to Evaluate The Efficacy and Safety of MK - 3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor - Negative Breast Cancer with ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (yPN +) After Neoadjuvant Chemotherapy

On October 2, 2015, the FDA approved the immunotherapy drug pembrolizumab (Keytruda ®), made by Merck, as second - line treatment for patients with lung cancer, the leading cause of cancer - related death in the U.S. and the world.

The FDA granted approval to pembrolizumab (Keytruda, Merck), a checkpoint immunotherapy that targets the PD - 1 pathway, as a second - line treatment for advanced bladder cancer.

The FDA granted accelerated approval to pembrolizumab (Keytruda, Merck) as a second - line treatment for all metastatic solid tumor types classified as MSI - hi (high microsatellite instability) or dMMR (deficient DNA mismatch repair).

In melanoma patients who are also treated with the immune therapy pembrolizumab after surgery, the risk of recurrence of the disease is almost twice as small as in patients who receive a placebo.

The FDA also approved another immunotherapy drug, Merck's pembrolizumab, known commercially as Keytruda, for patients with tumors harboring this defect regardless of cancer type.

The Food and Drug Administration has cleared four checkpoint inhibitors for adults: Yervoy, also known as ipilimumab; Keytruda, or pembrolizumab; Opdivo, or nivolumab, and Tecentriq, or atezolizumab.

Because they stimulate the immune system rather than introducing an agent or process that can kill healthy cells along with the malignant ones, these therapies — which include commonly prescribed treatments such as trastuzumab (Herceptin), pembrolizumab (Keytruda) and nivolumab (Opdivo)-- have been noteworthy not only for their effectiveness but for their tolerability.

In 2015 and 2016, the FDA expanded its approval of pembrolizumab and nivolumab as first - line treatments for unresectable or metastatic melanoma, regardless of mutational status.

Based primarily on clinical trials led by Arjun V. Balar, MD, assistant professor of medicine and director of the Genitourinary Medical Oncology Program, the FDA approved atezolizumab (Tecentriq ®) and pembrolizumab (Keytruda ®) as first - line treatments for these particularly frail patients with advanced bladder cancer in early 2017.

Led by Leena Gandhi, MD, PhD, associate professor of medicine and director of thoracic medical oncology, researchers from the KEYNOTE - 021 study demonstrated for the first time that combining an immune checkpoint inhibitor — in this case, pembrolizumab — with a platinum - doublet chemotherapy regimen might be more effective than chemotherapy alone as first - line treatment for advanced, non-squamous NSCLC.

Pembrolizumab, which has already been shown safe and effective as monotherapy for advanced, non-squamous non-small cell lung cancer (NSCLC), might also be an effective component in combination therapy for the disease.

At the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting, we presented monotherapy data of nine patients who received G100 with radiation (no pembrolizumab) that showed 100 % DCR rate, with 44 % of the patients achieved a partial response (PR) based on WHO criteria, which requires at least a 50 % tumor reduction to qualify as a PR.

Immune Design entered into clinical collaboration agreements with Merck, known as MSD outside the U.S. and Canada, to evaluate the safety and efficacy of two Immune Design immuno - oncology investigative agents, G100 and LV305, separately combined with KEYTRUDA ® (pembrolizumab), Merck's anti-PD-1 therapy, in Phase 1 trials in patients with non-Hodgkin's lymphoma (NHL) and melanoma, respectively.